MedTrace Logo

Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures

NCT00515619 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 376

Last updated 2017-08-28

Study results available
· View outcomes & findings →

Summary

The main purpose of this trial is to determine safety and efficacy of Lacosamide under long term therapy.

Conditions

Interventions

DRUG

Lacosamide

50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • Australia
  • Croatia
  • Czechia
  • Finland
  • France
  • Germany
  • Hungary
  • Lithuania
  • Poland
  • Russia
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00515619 on ClinicalTrials.gov